Clinical Trials
5 trialsNCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT04319159 2021-11-11
Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT02464709 2019-08-28
Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Joint Authority for Päijät-Häme Social and Health Care
Phase 4 Completed
NCT02799069 2017-04-28
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02799082 2017-04-06
Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.
Biofrontera Bioscience GmbH
Phase 3 Completed